This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Humana (HUM) Q4 Earnings Miss on Higher Costs, '25 Target Pulled
by Zacks Equity Research
Humana (HUM) expects 2024 revenues to increase to around $113 billion.
Elevance (ELV) Q4 Earnings Beat on Premium Growth, Dividend Hiked
by Zacks Equity Research
Elevance Health (ELV) expects 2024 premium revenues to remain in line with the 2023 level.
Are Medical Stocks Lagging Brookdale Senior Living (BKD) This Year?
by Zacks Equity Research
Here is how Brookdale Senior Living (BKD) and Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (CHGCY) have performed compared to their sector so far this year.
Are Investors Undervaluing Brookdale Senior Living (BKD) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Molina Healthcare (MOH) Up 26.9% in 6 Months: What Lies Ahead?
by Zacks Equity Research
Molina Healthcare (MOH) is likely to keep growing on the back of increases in investment income and Medicare premiums.
Why You Should Retain Elevance (ELV) Stock in Your Portfolio
by Zacks Equity Research
Elevance's (ELV) Carelon unit is expected to benefit from improving performance in the Behavioral Health business and post-acute care services.
UnitedHealth (UNH) Stock Declines 3.4% on High Medical Costs
by Zacks Equity Research
As more seniors resume elective procedures, claims rise in UnitedHealth's (UNH) Medicare Advantage business.
Elevance Health (ELV) & Verizon Partner to Bring Health Equity
by Zacks Equity Research
Elevance Health (ELV) launches a new program with an Affordable Connectivity Program offering free smartphones to eligible members.
Brookdale (BKD) Sees Growth in December 2023 Occupancy Volumes
by Zacks Equity Research
Brookdale (BKD) witnesses a continuous streak of 26 months of year-over-year increases in the weighted average occupancy level.
Why Acadia (ACHC) is a Smart Addition to Your Portfolio Now
by Zacks Equity Research
Acadia Healthcare's (ACHC) top line is poised to gain from rising admissions and patient days.
Fast-paced Momentum Stock Brookdale (BKD) Is Still Trading at a Bargain
by Zacks Equity Research
Brookdale (BKD) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.
Why Community Health (CYH) Shares Are Attracting Investors Now
by Zacks Equity Research
We expect Community Health's (CYH) occupancy rate to continue moving upward, reflecting improving utilization of its facilities and services.
Ensign (ENSG) Buys 2 Nursing Facilities in Tennessee & Nevada
by Zacks Equity Research
The acquisition deals have increased Ensign's (ENSG) portfolio to encompass 299 healthcare operations spanning 14 states.
Brookdale (BKD) Concludes Transactions to Extend Debt Repayment
by Zacks Equity Research
Brookdale (BKD) completes two financing transactions to push its debt maturities until September 2025, thereby relieving it from the debt repayment burden for next year and focusing on core operations.
Brookdale's (BKD) November 2023 Weighted Average Occupancy Up
by Zacks Equity Research
Brookdale (BKD) witnesses 25 straight months of year-over-year increase in weighted average occupancy level.
Brookdale Senior (BKD) Shares Rise 1.9% Despite Q3 Earnings Miss
by Zacks Equity Research
Brookdale Senior (BKD) expects adjusted EBITDA to be within the $77-$82 million range in the fourth quarter.
Brookdale's (BKD) September 2023 Occupancy Volumes Increase
by Zacks Equity Research
Brookdale (BKD) has seen a continuous streak of 23 months of year-over-year increases in the weighted average occupancy level.
Brookdale's (BKD) August 2023 Occupancy & Move-in Volumes Rise
by Zacks Equity Research
Brookdale (BKD) has witnessed 22 straight months of year-over-year increases in the weighted average occupancy level.
Brookdale Senior (BKD) Shares Jump 18.7% Since Q2 Earnings Beat
by Zacks Equity Research
Brookdale Senior (BKD) expects adjusted EBITDA to be within the $73-$78 million range in the third quarter.
Brookdale (BKD) Reports Occupancy Growth for 20 Straight Months
by Zacks Equity Research
The continuous uptick observed in Brookdale's (BKD) weighted average occupancy level is expected to inflict a favorable impact on its resident fee revenues in the days ahead.
Here's Why Buying Brookdale (BKD) Stock is a Prudent Move Now
by Zacks Equity Research
For the second quarter, Brookdale (BKD) expects RevPAR growth to be in the range of 11.5-12%.
Is Exact Sciences (EXAS) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Exact Sciences (EXAS) and Brookdale Senior Living (BKD) have performed compared to their sector so far this year.
Brookdale (BKD) May 2023 Occupancy Rises: Better Days Ahead?
by Zacks Equity Research
Brookdale (BKD) has witnessed 19 straight months of year-over-year increases in weighted average occupancy level.
Are Medical Stocks Lagging Akebia Therapeutics (AKBA) This Year?
by Zacks Equity Research
Here is how Akebia Therapeutics (AKBA) and Brookdale Senior Living (BKD) have performed compared to their sector so far this year.
Brookdale (BKD) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
by Zacks Equity Research
Brookdale (BKD) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.